These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28106982)

  • 1. A Novel Iron(II) Preferring Dopamine Agonist Chelator as Potential Symptomatic and Neuroprotective Therapeutic Agent for Parkinson's Disease.
    Das B; Kandegedara A; Xu L; Antonio T; Stemmler T; Reith MEA; Dutta AK
    ACS Chem Neurosci; 2017 Apr; 8(4):723-730. PubMed ID: 28106982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses α-syn- and MPTP-induced toxicities in vivo.
    Das B; Rajagopalan S; Joshi GS; Xu L; Luo D; Andersen JK; Todi SV; Dutta AK
    Neuropharmacology; 2017 Sep; 123():88-99. PubMed ID: 28533164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson's disease.
    Ghosh B; Antonio T; Reith ME; Dutta AK
    J Med Chem; 2010 Mar; 53(5):2114-25. PubMed ID: 20146482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treatment of Parkinson's Disease.
    Das B; Vedachalam S; Luo D; Antonio T; Reith ME; Dutta AK
    J Med Chem; 2015 Dec; 58(23):9179-95. PubMed ID: 26555041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, Synthesis, and Pharmacological Characterization of Carbazole Based Dopamine Agonists as Potential Symptomatic and Neuroprotective Therapeutic Agents for Parkinson's Disease.
    Elmabruk A; Das B; Yedlapudi D; Xu L; Antonio T; Reith MEA; Dutta AK
    ACS Chem Neurosci; 2019 Jan; 10(1):396-411. PubMed ID: 30301349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel multifunctional dopamine D
    Luo D; Sharma H; Yedlapudi D; Antonio T; Reith MEA; Dutta AK
    Bioorg Med Chem; 2016 Nov; 24(21):5088-5102. PubMed ID: 27591013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multifunctional D2/D3 agonist D-520 with high in vivo efficacy: modulator of toxicity of alpha-synuclein aggregates.
    Modi G; Voshavar C; Gogoi S; Shah M; Antonio T; Reith ME; Dutta AK
    ACS Chem Neurosci; 2014 Aug; 5(8):700-17. PubMed ID: 24960209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective Effect of a New 7,8-Dihydroxycoumarin-Based Fe
    Aguirre P; García-Beltrán O; Tapia V; Muñoz Y; Cassels BK; Núñez MT
    ACS Chem Neurosci; 2017 Jan; 8(1):178-185. PubMed ID: 27806193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity.
    Biswas S; Hazeldine S; Ghosh B; Parrington I; Kuzhikandathil E; Reith ME; Dutta AK
    J Med Chem; 2008 May; 51(10):3005-19. PubMed ID: 18410082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.
    Ghosh B; Antonio T; Zhen J; Kharkar P; Reith ME; Dutta AK
    J Med Chem; 2010 Feb; 53(3):1023-37. PubMed ID: 20038106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. D-512, a novel dopamine D
    Lindenbach D; Das B; Conti MM; Meadows SM; Dutta AK; Bishop C
    Br J Pharmacol; 2017 Sep; 174(18):3058-3071. PubMed ID: 28667675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment.
    Shao YM; Ma X; Paira P; Tan A; Herr DR; Lim KL; Ng CH; Venkatesan G; Klotz KN; Federico S; Spalluto G; Cheong SL; Chen YZ; Pastorin G
    PLoS One; 2018; 13(1):e0188212. PubMed ID: 29304113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural modifications of neuroprotective anti-Parkinsonian (-)-N6-(2-(4-(biphenyl-4-yl)piperazin-1-yl)-ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264): an effort toward the improvement of in vivo efficacy of the parent molecule.
    Modi G; Antonio T; Reith M; Dutta A
    J Med Chem; 2014 Feb; 57(4):1557-72. PubMed ID: 24471976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors.
    Millan MJ; Iob L; Péglion JL; Dekeyne A
    Psychopharmacology (Berl); 2007 Apr; 191(3):767-82. PubMed ID: 17047933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole.
    Albrecht S; Buerger E
    Curr Med Res Opin; 2009 Dec; 25(12):2977-87. PubMed ID: 19842998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.
    Zheng H; Weiner LM; Bar-Am O; Epsztejn S; Cabantchik ZI; Warshawsky A; Youdim MB; Fridkin M
    Bioorg Med Chem; 2005 Feb; 13(3):773-83. PubMed ID: 15653345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease.
    Piercey MF
    Clin Neuropharmacol; 1998; 21(3):141-51. PubMed ID: 9617505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotection and dopamine agonists.
    Schapira AH
    Neurology; 2002 Feb; 58(4 Suppl 1):S9-18. PubMed ID: 11909981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine D₂/D₃ agonists with potent iron chelation, antioxidant and neuroprotective properties: potential implication in symptomatic and neuroprotective treatment of Parkinson's disease.
    Gogoi S; Antonio T; Rajagopalan S; Reith M; Andersen J; Dutta AK
    ChemMedChem; 2011 Jun; 6(6):991-5. PubMed ID: 21567969
    [No Abstract]   [Full Text] [Related]  

  • 20. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats.
    Shachar DB; Kahana N; Kampel V; Warshawsky A; Youdim MB
    Neuropharmacology; 2004 Feb; 46(2):254-63. PubMed ID: 14680763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.